Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$16.07 +2.6%	$14.98	$9.57 ▼ $30.41	$2.16B	0.96	1.54 million shs	1.44 million shs
BCYC Bicycle Therapeutics	$7.28 +2.5%	$8.19	$6.10 ▼ $28.67	$491.70M	1.46	392,651 shs	637,230 shs
BHC Bausch Health Cos	$6.43 +0.7%	$5.11	$3.96 ▼ $9.85	$2.36B	0.28	2.61 million shs	2.32 million shs
NAMS NewAmsterdam Pharma	$18.45 +0.7%	$18.68	$14.06 ▼ $27.29	$2.06B	-0.03	707,775 shs	755,738 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+2.62%	+2.88%	+4.55%	+16.28%	-38.80%
BCYC Bicycle Therapeutics	+2.54%	-1.75%	-9.34%	-18.84%	-63.98%
BHC Bausch Health Cos	+0.71%	+3.75%	+40.13%	-0.93%	-5.38%
NAMS NewAmsterdam Pharma	+0.65%	+1.37%	+8.47%	-15.21%	-6.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6903 of 5 stars	3.4	1.0	3.4	3.0	2.5	0.0
BCYC Bicycle Therapeutics	3.6464 of 5 stars	4.4	1.0	0.0	3.1	4.2	0.6
BHC Bausch Health Cos	3.6081 of 5 stars	1.9	2.0	4.0	3.3	3.3	0.6
NAMS NewAmsterdam Pharma	3.0383 of 5 stars	3.5	2.0	0.0	2.6	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	172.02% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	243.41% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	15.43% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	132.46% Upside

Current Analyst Ratings Breakdown

Latest BCYC, NAMS, BHC, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	625.15	N/A	N/A	$1.54 per share	10.44
BCYC Bicycle Therapeutics	$35.28M	14.29	N/A	N/A	$11.48 per share	0.63
BHC Bausch Health Cos	$9.63B	0.25	$7.84 per share	0.82	($0.89) per share	-7.22
NAMS NewAmsterdam Pharma	$45.56M	45.46	N/A	N/A	$8.20 per share	2.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.42	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.38	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)

Latest BCYC, NAMS, BHC, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BCYC Bicycle Therapeutics	N/A	14.86	14.86
BHC Bausch Health Cos	N/A	1.35	0.97
NAMS NewAmsterdam Pharma	N/A	19.98	19.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BCYC Bicycle Therapeutics	86.15%
BHC Bausch Health Cos	78.65%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BCYC Bicycle Therapeutics	22.90%
BHC Bausch Health Cos	8.05%
NAMS NewAmsterdam Pharma	20.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable

BCYC, NAMS, BHC, and ARWR Headlines

Recent News About These Companies

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Purchases 1,260 Shares

June 26 at 8:59 PM | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Buys 2,520 Shares

June 26 at 8:58 PM | marketbeat.com

First Week of February 2026 Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq

June 24 at 10:55 PM | nasdaq.com

NewAmsterdam Pharma Company N.V. (NAMS) - Yahoo Finance

June 24 at 5:54 PM | finance.yahoo.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from Analysts

June 24 at 2:40 AM | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Lowered to "Sell" Rating by Wall Street Zen

June 22, 2025 | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Downgraded by Wall Street Zen to "Sell"

June 21, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up - Time to Buy?

June 20, 2025 | marketbeat.com

James N. Topper Acquires 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

June 19, 2025 | insidertrades.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Rating of "Buy" by Analysts

June 19, 2025 | marketbeat.com

Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug

June 18, 2025 | investing.com

James N. Topper Purchases 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

June 18, 2025 | marketbeat.com

Insider Selling: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Sells 100,000 Shares of Stock

June 18, 2025 | marketbeat.com

Citigroup Begins Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)

June 18, 2025 | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Earns Buy Rating from Analysts at Citigroup

June 17, 2025 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Handelsbanken Fonder AB

June 13, 2025 | marketbeat.com

5NAMS : What Analysts Are Saying About NewAmsterdam Pharma...

June 12, 2025 | benzinga.com

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities

June 12, 2025 | tipranks.com

NewAmsterdam Pharma (NASDAQ:NAMS) Given Buy Rating at Needham & Company LLC

June 12, 2025 | marketbeat.com

Stifel Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation

June 11, 2025 | msn.com

NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel

June 11, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, NAMS, BHC, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.07 +0.41 (+2.62%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$15.66 -0.41 (-2.52%)

As of 06/26/2025 07:45 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bicycle Therapeutics NASDAQ:BCYC

$7.28 +0.18 (+2.54%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$7.28 0.00 (0.00%)

As of 06/26/2025 04:13 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bausch Health Cos NYSE:BHC

$6.42 +0.05 (+0.71%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$6.48 +0.05 (+0.78%)

As of 04:28 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

NewAmsterdam Pharma NASDAQ:NAMS

$18.45 +0.12 (+0.65%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$18.45 +0.00 (+0.03%)

As of 06/26/2025 04:04 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time